Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02697916 · ClinicalTrials.gov registry record · NA
Aspirin Dosing: A Patient-Centric Trial Assessing Benefits and Long-term
A NA study, sponsored by Duke University.
- Completed
- Registry status
- NA
- Development phase
- 15,076
- Enrollment target
NCT02697916: Completed NA study, sponsored by Duke University.
NCT02697916 is a NA study that has completed, run by Duke University. The registered enrollment target is 15,076 participants, above the 1,403-participant average among 58,714 other NA trials with a reported enrollment target (975% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02697916, a NA study, has completed, sponsored by Duke University.
- COMPLETED
- Registry status
- NA
- Development phase
- 15,076 participants
- Enrollment target
Study Summary
ADAPTABLE is a pragmatic clinical trial in which 15,000 patients who are at high risk for ischemic events will be randomly assigned in a 1:1 ratio to receive an aspirin dose of 81 mg/day vs. 325 mg/day. Study participants will be enrolled over 38 months. Maximum follow-up will be 50 months. The purpose of the study is to identify the optimal dose of aspirin for secondary prevention in patients with Atherosclerotic cardiovascular disease (ASCVD). The primary endpoint is a composite of all-cause death, hospitalization for MI, or hospitalization for stroke. The primary safety endpoint is hospitalization for major bleeding with an associated blood product transfusion.
Interventions
- DRUG aspirin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15,076 participants |
| Start Date | 2016-04 |
| Est. Completion | 2020-06-30 |
| Phase | NA |
What the finished NCT02697916 record still lists
NCT02697916 is an interventional study that assigns participants to a tested intervention. Its 15,076 participants enrollment target places it among the larger protocols in the corpus, above the 1,403-participant average among 58,714 other NA trials with a reported enrollment target (975% higher).
The record links to 0 conditions, and to 1 intervention - of which aspirin is the first listed.
NCT02697916 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02697916 about?
NCT02697916 is a clinical study titled "Aspirin Dosing: A Patient-Centric Trial Assessing Benefits and Long-term". ADAPTABLE is a pragmatic clinical trial in which 15,000 patients who are at high risk for ischemic events will be randomly assigned in a 1:1 ratio to receive an aspirin dose of 81 mg/day vs. 325 mg/day. Study participants will be enrolled over 38 months. Maximum follow-up will be 50 months. The purp...
What is the current status of trial NCT02697916?
This trial is currently completed. It is a NA study. The enrollment target is 15,076 participants. The study started on 2016-04. Estimated completion is 2020-06-30.
What interventions are being tested in trial NCT02697916?
The interventions under investigation include: aspirin (DRUG).
Who is sponsoring clinical trial NCT02697916?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02697916's enrollment target sits among peer trials
15,076 13th of 2000 higher than 1,988 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT07000357 · 15,100 participants · Phase 3
A Phase III Study of AZD0780 on Major Adverse CV Events in Patients With a History of ASCVD Events or at High Risk for a First Event
- NCT00857922 · 15,000 participants
Neurosciences Research Repository
- NCT01137643 · 15,000 participants
Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer
- NCT01550575 · 15,000 participants
Patient Retrospective Outcomes (PRO)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia